Contact Lens Solution for Refractive Errors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two contact lens cleaning solutions, BL-3100-NBR03 multi-purpose solution and renu® Advanced Formula multi-purpose solution, to determine which is safer and more effective for daily use. Participants will use one of the solutions for three months while wearing contact lenses replaced monthly. It suits individuals who regularly wear soft contact lenses and clean them daily without hydrogen-peroxide-based solutions. As an unphased trial, this study allows participants to contribute to research that could enhance daily contact lens care.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot participate if you are using any medications that affect eye health or contact lens performance.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that the BL-3100-NBR03 multi-purpose solution is currently being tested for safety. Specific information from past studies is lacking, so it is uncertain how well people tolerate it. As this is an early-stage trial, comprehensive safety data may not yet be available, and safety is still under evaluation.
In contrast, the renu® Advanced Formula multi-purpose solution is already available in stores, indicating it has been deemed safe for most people when used for cleaning and disinfecting contact lenses.
So far, there have been no major reports of side effects from either solution. However, participants should report any discomfort or issues during the trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the BL-3100-NBR03 multi-purpose solution because it promises to redefine how we clean and disinfect contact lenses. Unlike typical solutions that rely on well-known disinfectants, BL-3100-NBR03 might incorporate a novel combination of ingredients that enhance its cleaning power while being gentle on the eyes. This could mean fewer irritations and a more comfortable experience for contact lens wearers. Meanwhile, the renu® Advanced Formula serves as a trusted benchmark in the trial, known for its reliable cleaning performance and safety profile.
What evidence suggests that this trial's treatments could be effective for eye care?
This trial will compare the effectiveness of two contact lens solutions: BL-3100-NBR03 and renu® Advanced Formula. Studies have shown that contact lens solutions effectively clean and disinfect lenses by removing dirt and killing bacteria that can cause eye infections. Researchers are studying the BL-3100-NBR03 solution, which participants in this trial may receive, for its ability to clean and maintain lens comfort. Meanwhile, the renu® Advanced Formula, another treatment option in this trial, has a proven record of keeping lenses clean and comfortable while reducing eye irritation. Both products aim to ensure that lenses are safe and comfortable for daily use.16789
Who Is on the Research Team?
Daniel Donatello
Principal Investigator
Bausch & Lomb Incorporated
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants wear dispensed study lenses on a daily wear basis for three months with scheduled in-office replacement of study lenses at the 1-Month and 2-Month Follow-Up Visits
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BL-3100-NBR03 multi-purpose solution
- renu® Advanced Formula multi-purpose solution
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bausch & Lomb Incorporated
Lead Sponsor
Dr. Christina Ackermann
Bausch & Lomb Incorporated
Chief Medical Officer since 2023
MD from Harvard Medical School
Brent Saunders
Bausch & Lomb Incorporated
Chief Executive Officer since 2023
BA from the University of Pittsburgh, JD and MBA from Temple University